UNSPSC 51284036: Oxytetracycline anhydrous

This classification denotes a tetracycline antibiotic with the molecular formula C22H24N2O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SLF0D9077S, chemically known as oxytetracycline (anhydrous) [hsdb], but more generally known as oxytetracycline anhydrous, which bears US NIH Compound Identifier 5280972. European Medicines Agency schedules oxytetracycline anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09579MIG.

Most nations, for tariff purposes, schedule oxytetracycline anhydrous under HS 29413000. Oxytetracycline anhydrous bears US NLM identifiers UMLS ID C2698682 and NCI Concept Code C74596. SMILES: C[C@]1(C2CCCC(C2C(=O)C3=C([C@]4([C@@H]([C@H]([C@@H]31)O)[C@@H](C(=C(C4=O)C(=O)N)O)N(C)C)O)O)O)O.

UNSPSC 51284036 Oxytetracycline anhydrous is a Commodity code that maps poorly to recent state and local procurement activity; the source shows no direct solicitations for oxytetracycline or tetracycline-class antibiotics under this code. Instead, recent opportunities tagged to this code address a broader pharmaceutical and medical supply landscape—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and over-the-counter products. The mismatch suggests either tagging inconsistency in source systems or a code whose nominal scope diverges sharply from how state and local procurement offices classify pharmaceutical and medical supply work in practice. Issuing bodies in the recent block span county health departments (Seminole County, Florida), state health agencies (Texas HHS Commission), municipal procurement offices (City of Tampa), and multi-state cooperative purchasing alliances (MMCAP, serving Minnesota, Oregon, and participating states). The City of Tampa's IFB for medical and first aid supplies designated $700,000 estimated contract value with a sheltered-market set-aside for certified Small Local Business Enterprises (SLBEs) and a 5 percent SLBE bid discount not to exceed $10,000; the Seminole County naloxone procurement required quarterly delivery of 1,900 units of naloxone and 800 safe drug deactivation systems annually on an IFB basis with a two-year initial term and one-year renewal option.

Geographic spread across recent opportunities includes Florida (Seminole County, Tampa), Texas, and the Upper Midwest through MMCAP's multi-state cooperative mechanism. The Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, illustrates cooperative purchasing scale—pricing weighted 75 percent, with mandatory compliance to cGMP and Drug Supply Chain Security Act (DSCSA), product availability by May 15, 2026, and awards effective July 1, 2026 across two-year initial terms. Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) on a Direct-to-Manufacturer Prescriptions program sought vendor capabilities for direct state-to-manufacturer relationships outside traditional pharmacy benefit manager and wholesaler channels, signaling potential procurement model innovation in state pharmacy benefit design. The code shows activity but with material category divergence from its stated commodity scope; pursuit decisions should weight whether your firm's capabilities align with the actual work being solicited (naloxone, emergency medical supplies, generic pharmaceuticals, and direct pharmacy programs) rather than assuming oxytetracycline-specific demand.